CN119548484A - 治疗cdk4/6抑制剂耐药性癌症的方法 - Google Patents

治疗cdk4/6抑制剂耐药性癌症的方法 Download PDF

Info

Publication number
CN119548484A
CN119548484A CN202411710355.XA CN202411710355A CN119548484A CN 119548484 A CN119548484 A CN 119548484A CN 202411710355 A CN202411710355 A CN 202411710355A CN 119548484 A CN119548484 A CN 119548484A
Authority
CN
China
Prior art keywords
esr1
cdk4
resistant
cancer
estrogen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411710355.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·帕特尔
T·比哈尼
H·阿尔特
N·陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Pharmaceuticals Inc
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of CN119548484A publication Critical patent/CN119548484A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411710355.XA 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法 Pending CN119548484A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06
US62/776,323 2018-12-06
PCT/US2019/065005 WO2020118213A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer resistant to cdk4/6 inhibitors
CN201980081052.7A CN113164779A (zh) 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980081052.7A Division CN113164779A (zh) 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法

Publications (1)

Publication Number Publication Date
CN119548484A true CN119548484A (zh) 2025-03-04

Family

ID=69063871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980081052.7A Pending CN113164779A (zh) 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法
CN202411710355.XA Pending CN119548484A (zh) 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201980081052.7A Pending CN113164779A (zh) 2018-12-06 2019-12-06 治疗cdk4/6抑制剂耐药性癌症的方法

Country Status (17)

Country Link
US (2) US20210330612A1 (enExample)
EP (1) EP3890834A1 (enExample)
JP (1) JP7504097B2 (enExample)
KR (1) KR20210100137A (enExample)
CN (2) CN113164779A (enExample)
AU (1) AU2019395093B2 (enExample)
BR (1) BR112021010110A2 (enExample)
CA (1) CA3121930A1 (enExample)
EA (1) EA202191283A1 (enExample)
IL (1) IL283659A (enExample)
JO (1) JOP20210137A1 (enExample)
MA (1) MA54388A (enExample)
MX (1) MX2021006411A (enExample)
PH (1) PH12021551319A1 (enExample)
SG (1) SG11202105531XA (enExample)
UA (1) UA130036C2 (enExample)
WO (1) WO2020118213A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
CA3202592A1 (en) * 2020-12-14 2022-06-23 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN116327894A (zh) * 2023-04-10 2023-06-27 上海市第一妇婴保健院 一种治疗kras突变的卵巢癌的组合药物及其应用
WO2025202871A1 (en) * 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX393599B (es) * 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
KR102881465B1 (ko) * 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) * 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Also Published As

Publication number Publication date
PH12021551319A1 (en) 2022-05-16
AU2019395093A1 (en) 2021-06-24
UA130036C2 (uk) 2025-10-22
MA54388A (fr) 2021-10-13
AU2019395093B2 (en) 2025-01-23
MX2021006411A (es) 2021-07-21
JOP20210137A1 (ar) 2023-01-30
JP2022511498A (ja) 2022-01-31
EP3890834A1 (en) 2021-10-13
US20250319044A1 (en) 2025-10-16
CN113164779A (zh) 2021-07-23
EA202191283A1 (ru) 2021-10-13
IL283659A (en) 2021-07-29
KR20210100137A (ko) 2021-08-13
WO2020118213A1 (en) 2020-06-11
US20210330612A1 (en) 2021-10-28
CA3121930A1 (en) 2020-06-11
BR112021010110A2 (pt) 2021-08-24
JP7504097B2 (ja) 2024-06-21
SG11202105531XA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
JP7504097B2 (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
JP2022509262A (ja) 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
JP7497353B2 (ja) Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
CA3036568A1 (en) Methods for treating ovarian cancer
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
WO2024054898A1 (en) Onvansertib and parp inhibitor combination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination